If you are looking for an answer to the question What is Artificial Intelligence? and you only have a minute, then here's the definition the Association for the Advancement of Artificial Intelligence offers on its home page: "the scientific understanding of the mechanisms underlying thought and intelligent behavior and their embodiment in machines."
However, if you are fortunate enough to have more than a minute, then please get ready to embark upon an exciting journey exploring AI (but beware, it could last a lifetime) …
IBM has partnered with pharmaceutical giant Pfizer to design an artificial intelligence (AI) model to predict the eventual onset of the neurological disease seven years before symptoms appear. Alzheimer's is currently incurable and is often diagnosed too late to prevent it from accelerating. Symptoms for the disease include the gradual degradation of memory, confusion, and difficulty in completing once-familiar daily tasks. Published in The Lancet eClinical Medicine, the researchers used small samples of language data from clinical verbal tests provided by the Framingham Heart Study, a long-term study that has been tracking the health of more than 5,000 people and their families since 1948, to train the AI models. The AI model's ability was then verified against data samples from a group of healthy individuals who eventually did and did not develop the disease later in life.
Researchers from the Moscow Institute of Physics and Technology, Ivannikov Institute for System Programming, and the Harvard Medical School-affiliated Schepens Eye Research Institute have developed a neural network capable of recognizing retinal tissues during the process of their differentiation in a dish. Unlike humans, the algorithm achieves this without the need to modify cells, making the method suitable for growing retinal tissue for developing cell replacement therapies to treat blindness and conducting research into new drugs. The study was published in Frontiers in Cellular Neuroscience. In multicellular organisms, the cells making up different organs and tissues are not the same. They have distinct functions and properties, acquired in the course of development. They start out the same, as so-called stem cells, which have the potential to become any kind of cell the mature organism incorporates.
Amazon's naked ambition to become part of everyone's daily lives was on full display this week at its annual hardware event. It announced a slew of new Alexa-powered devices, including a home surveillance drone, a suite of Ring-branded car alarm systems, and miscellany like an adorable little kids' Echo device. But it's clear Amazon's strategy has shifted, even if only for a product cycle, from going wide to going deep. Last year, Amazon baked its virtual assistant into any household device that could accommodate a chip. Its list of new widgets with Alexa seemed a mile long and included a menagerie of home goods, like lamps and microwaves.
Lockheed Martin has been selected as the main contractor to conduct a study on how to provide the US Navy with large, autonomous ships that can operate for extended periods without a crew. Part of the Navy's Large Unmanned Surface Vessel (LUSV) competition, Lockheed is working with Portland, Oregon-based shipbuilder Vigor Works, LLC, and will provide program management, platform integration, systems engineering, combat management, automation, and cybernetic expertise. With the biggest costs of building and operating a ship revolving around putting a crew aboard it, the US and other navies are very interested in creating unmanned or man-optional ships that can carry out both routine and extremely hazardous duties, leaving sailors to handle the sort of executive and complex tasks that still require a human touch. These autonomous ships of the future could be anything from small autonomous patrol craft, to sub hunters, to full-blown combat submarines. Such craft could, ideally, leave port on their own, remain at sea for months at a time, and then return autonomously for refit and maintenance.
At a Friday event, Elon Musk revealed more details about his mysterious neuroscience company Neuralink and its plans to connect computers to human brains. While the development of this futuristic-sounding tech is still in its early stages, the presentation was expected to demonstrate the second version of a small, robotic device that inserts tiny electrode threads through the skull and into the brain. Musk said ahead of the event he would "show neurons firing in real-time. And he did just that. At the event, Musk showed off several pigs that had prototypes of the neural links implanted in their head, and machinery that was tracking those pigs' brain activity in real time. The billionaire also announced the Food and Drug Administration had awarded the company a breakthrough device authorization, which can help expedite research on a medical device. Like building underground car tunnels and sending private rockets to Mars, this Musk-backed endeavor is incredibly ambitious, but Neuralink ...
Our squishy, salty brains are capable of doing incredible things -- from commanding us to walk to solving complex questions about our world. Scientists and science-fiction authors alike have yearned to understand (and even) control our brains, but they've thus far been an incredibly complex nut to crack. Intriguingly, the development of a new, biocompatible polymer coating for electronic implants by a team of researchers at the University of Delaware could be the key to better understanding this biological black box. These polymers would not only leave less scarring on biological tissue than inorganic-coated electronics but would also allow scientists to fine-tune the sensitivities of polymers -- which could allow for the creation of early warning systems for the presence of harmful diseases. Furthermore, as these devices continue to mature, scientists say they could be the answer to creating an effective human brain-A.I. interface in the future.
Now that data is the most transformative asset in business, it's essential to prepare for what lies ahead, and to adjust strategies accordingly in order to successfully face the business landscape of tomorrow. We have identified 10 trends happening in 2020 that will be catalysts and enablers for change, and they will drive companies to enhance capabilities to stay at the forefront of innovation. They will allow data to be consumed dynamically and in different ways, causing people to search and think of new ways to use data. Given Trends These trends are a must, and they require action now. It's apparent that legacy on-premises platforms have failed to make data accessible to all users.
This would allow to expand the applications of the technology for multiple fields including the drug discovery and development of cell replacement therapies to treat blindness. In multicellular organisms, the cells making up different organs and tissues are not the same. They have distinct functions and properties, acquired in the course of development. They start out the same, as so-called stem cells, which have the potential to become any kind of cell the mature organism incorporates. They then undergo differentiation by producing proteins specific to certain tissues and organs. The most advanced technique for replicating tissue differentiation in vitro relies on 3D cell aggregates called organoids.
Artificial intelligence (AI) holds promise for enabling earlier detection of pancreatic cancer, which is crucial to saving lives. The potential of AI is showcased in a study to be presented at the ESMO World Congress on Gastrointestinal Cancer, 1–4 July 2020. Overall, 12 in every 100,000 people develop pancreatic cancer. This means that screening everyone would be inefficient and would expose many people to unnecessary tests and potential side-effects. Between 70-80% of patients are diagnosed at an advanced stage when it is too late for curative treatment and five years after diagnosis, just 6% of patients have survived.
A blood antibody (or serology) test that determines with incredible accuracy if someone has ever been infected with the COVID-19 coronavirus has received quick emergency-use approval (EUA) from the U.S. Food and Drug Administration. It was developed by Swiss multinational healthcare giant, F. Hoffmann-La Roche AG. The coronavirus that causes COVID-19 is SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2. The Roche antibody test, "Elecsys Anti-SARS-CoV-2," is 100% accurate at detecting antibodies in the blood and 99.8% accurate at ruling out the presence of antibodies (otherwise called the specificity rate). This means it provides no false negatives and very few false-positive tests. These rates help determine if a person has been exposed to SARS-CoV-2.